225 related articles for article (PubMed ID: 36069925)
1. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
[No Abstract] [Full Text] [Related]
2. COVID-19 mRNA Vaccine Booster During Pregnancy Increases Maternal and Fetal Antibodies.
Abbasi J
JAMA; 2022 Jul; 328(2):120-121. PubMed ID: 35731542
[No Abstract] [Full Text] [Related]
3. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
Regev-Yochay G; Gonen T; Gilboa M; Mandelboim M; Indenbaum V; Amit S; Meltzer L; Asraf K; Cohen C; Fluss R; Biber A; Nemet I; Kliker L; Joseph G; Doolman R; Mendelson E; Freedman LS; Harats D; Kreiss Y; Lustig Y
N Engl J Med; 2022 Apr; 386(14):1377-1380. PubMed ID: 35297591
[No Abstract] [Full Text] [Related]
4. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
5. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
Nat Commun; 2022 Jun; 13(1):3082. PubMed ID: 35654888
[TBL] [Abstract][Full Text] [Related]
6. mRNA Booster Improves a COVID-19 Vaccine's Effectiveness.
Kuehn BM
JAMA; 2022 May; 327(18):1749. PubMed ID: 35536258
[No Abstract] [Full Text] [Related]
7. Messenger RNA vaccines against SARS-CoV-2.
Topol EJ
Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
[TBL] [Abstract][Full Text] [Related]
8. Safety of mRNA-Based Vaccines for SARS CoV-2.
Barda B; Cerny A
Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
[TBL] [Abstract][Full Text] [Related]
9. Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.
Zhang R; Hung IF
Lancet Infect Dis; 2024 Jun; 24(6):558-559. PubMed ID: 38460526
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Jaycox JR; Lucas C; Yildirim I; Dai Y; Wang EY; Monteiro V; Lord S; Carlin J; Kita M; Buckner JH; Ma S; Campbell M; Ko A; Omer S; Lucas CL; Speake C; Iwasaki A; Ring AM
Nat Commun; 2023 Mar; 14(1):1299. PubMed ID: 36894554
[TBL] [Abstract][Full Text] [Related]
11. Variant-adapted COVID-19 booster vaccines.
Krammer F; Ellebedy AH
Science; 2023 Oct; 382(6667):157-159. PubMed ID: 37824671
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches for vaccine development.
Gebre MS; Brito LA; Tostanoski LH; Edwards DK; Carfi A; Barouch DH
Cell; 2021 Mar; 184(6):1589-1603. PubMed ID: 33740454
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
14. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
15. mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
Larkin HD
JAMA; 2022 Jun; 327(23):2280. PubMed ID: 35727270
[No Abstract] [Full Text] [Related]
16. Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
Dimopoulou D; Vartzelis G; Dasoula F; Tsolia M; Maritsi D
Ann Rheum Dis; 2022 Apr; 81(4):592-593. PubMed ID: 34844930
[No Abstract] [Full Text] [Related]
17. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine.
Takano T; Morikawa M; Adachi Y; Kabasawa K; Sax N; Moriyama S; Sun L; Isogawa M; Nishiyama A; Onodera T; Terahara K; Tonouchi K; Nishimura M; Tomii K; Yamashita K; Matsumura T; Shinkai M; Takahashi Y
Cell Rep Med; 2022 May; 3(5):100631. PubMed ID: 35545084
[TBL] [Abstract][Full Text] [Related]
18. Three, four or more: what's the magic number for booster shots?
Watson C
Nature; 2022 Feb; 602(7895):17-18. PubMed ID: 35091715
[No Abstract] [Full Text] [Related]
19. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
Björk J; Bonander C; Moghaddassi M; Rasmussen M; Malmqvist U; Inghammar M; Kahn F
Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514304
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
Bloomfield M; Parackova Z; Hanzlikova J; Lastovicka J; Sediva A
J Clin Immunol; 2022 Feb; 42(2):266-269. PubMed ID: 34718945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
